IN2014DN03325A - - Google Patents
Info
- Publication number
- IN2014DN03325A IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
- Authority
- IN
- India
- Prior art keywords
- compound
- directed
- composition
- sulphur
- selene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543510P | 2011-10-05 | 2011-10-05 | |
| NL2007536A NL2007536C2 (en) | 2011-10-05 | 2011-10-05 | Adjuvant compound. |
| US201261615566P | 2012-03-26 | 2012-03-26 | |
| PCT/NL2012/050694 WO2013051936A1 (en) | 2011-10-05 | 2012-10-04 | Adjuvant compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03325A true IN2014DN03325A (es) | 2015-06-26 |
Family
ID=48043964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3325DEN2014 IN2014DN03325A (es) | 2011-10-05 | 2012-10-04 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9314521B2 (es) |
| EP (1) | EP2763697B9 (es) |
| JP (1) | JP6099210B2 (es) |
| KR (1) | KR102053699B1 (es) |
| CN (1) | CN104244976B (es) |
| AU (1) | AU2012319265B2 (es) |
| BR (1) | BR112014008214B1 (es) |
| CA (1) | CA2886631C (es) |
| EA (1) | EA030741B1 (es) |
| ES (1) | ES2952644T3 (es) |
| IL (1) | IL231951B (es) |
| IN (1) | IN2014DN03325A (es) |
| MX (1) | MX356028B (es) |
| NL (1) | NL2007536C2 (es) |
| SG (1) | SG11201401291XA (es) |
| WO (1) | WO2013051936A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2907454C (en) | 2013-03-21 | 2021-05-04 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| WO2014207708A2 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| EP3148566B1 (en) | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
| BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
| PE20230343A1 (es) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CA3014515A1 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| JP7115803B2 (ja) | 2016-06-20 | 2022-08-09 | アイエスエー ファーマシューティカルズ ビー．ヴイ． | ペプチドワクチン製剤 |
| KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| WO2021110919A1 (en) | 2019-12-07 | 2021-06-10 | Isa Pharmaceuticals | Treatment of diseases related to hepatitis b virus |
| EP4100051A2 (en) | 2020-02-07 | 2022-12-14 | ISA Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| WO2021214297A1 (en) | 2020-04-23 | 2021-10-28 | Isa Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| CA3223357A1 (en) | 2021-07-12 | 2023-01-19 | Brigitte Elisa Anna Burm | Improved substance quantification in complex mixtures |
| WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
| WO2024079311A1 (en) | 2022-10-13 | 2024-04-18 | Isa Pharmaceuticals B.V. | Modified long peptides suitable for use in immunisation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| DE3937412A1 (de) * | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| CZ20014718A3 (cs) | 1999-06-30 | 2003-01-15 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| NL1012739C2 (nl) | 1999-07-29 | 2001-01-30 | Maasland Nv | Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer. |
| AU2002219711B8 (en) | 2000-12-08 | 2006-03-02 | Academisch Ziekenhuis Leiden | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| MXNL04000056A (es) | 2004-06-30 | 2006-01-11 | Mario Alberto Aguilera Rico | Sistema de construccion terra acero. |
| AU2007284656A1 (en) * | 2006-08-14 | 2008-02-21 | Thymon, L.L.C. | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 |
| ES2539812T3 (es) | 2007-03-26 | 2015-07-06 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos |
| CN101796070A (zh) | 2007-05-31 | 2010-08-04 | 莱顿教学医院 | p53肽疫苗 |
| CA3016942C (en) | 2007-05-31 | 2022-09-20 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| EA031379B1 (ru) * | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
-
2011
- 2011-10-05 NL NL2007536A patent/NL2007536C2/en active
-
2012
- 2012-10-04 BR BR112014008214-6A patent/BR112014008214B1/pt active IP Right Grant
- 2012-10-04 CA CA2886631A patent/CA2886631C/en active Active
- 2012-10-04 IN IN3325DEN2014 patent/IN2014DN03325A/en unknown
- 2012-10-04 SG SG11201401291XA patent/SG11201401291XA/en unknown
- 2012-10-04 EP EP12780309.6A patent/EP2763697B9/en active Active
- 2012-10-04 MX MX2014004114A patent/MX356028B/es active IP Right Grant
- 2012-10-04 CN CN201280059738.4A patent/CN104244976B/zh active Active
- 2012-10-04 KR KR1020147012025A patent/KR102053699B1/ko active IP Right Grant
- 2012-10-04 AU AU2012319265A patent/AU2012319265B2/en active Active
- 2012-10-04 ES ES12780309T patent/ES2952644T3/es active Active
- 2012-10-04 JP JP2014534504A patent/JP6099210B2/ja active Active
- 2012-10-04 EA EA201490709A patent/EA030741B1/ru not_active IP Right Cessation
- 2012-10-04 WO PCT/NL2012/050694 patent/WO2013051936A1/en active Application Filing
- 2012-10-04 US US14/349,652 patent/US9314521B2/en active Active
-
2014
- 2014-04-03 IL IL231951A patent/IL231951B/en active IP Right Grant
-
2016
- 2016-03-07 US US15/062,589 patent/US9770506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160250325A1 (en) | 2016-09-01 |
| ES2952644T3 (es) | 2023-11-02 |
| WO2013051936A1 (en) | 2013-04-11 |
| JP2014530808A (ja) | 2014-11-20 |
| EP2763697A1 (en) | 2014-08-13 |
| NL2007536C2 (en) | 2013-04-08 |
| JP6099210B2 (ja) | 2017-03-22 |
| MX356028B (es) | 2018-05-09 |
| EP2763697B8 (en) | 2023-07-12 |
| CA2886631C (en) | 2019-06-11 |
| SG11201401291XA (en) | 2014-05-29 |
| WO2013051936A9 (en) | 2013-09-12 |
| KR102053699B1 (ko) | 2019-12-09 |
| EP2763697C0 (en) | 2023-06-07 |
| MX2014004114A (es) | 2014-10-17 |
| IL231951B (en) | 2019-08-29 |
| US9314521B2 (en) | 2016-04-19 |
| IL231951A0 (en) | 2014-05-28 |
| BR112014008214A2 (pt) | 2017-06-13 |
| EP2763697B9 (en) | 2023-10-04 |
| AU2012319265B2 (en) | 2016-10-13 |
| NZ623869A (en) | 2015-11-27 |
| CA2886631A1 (en) | 2013-04-11 |
| US20150104473A1 (en) | 2015-04-16 |
| EA030741B1 (ru) | 2018-09-28 |
| BR112014008214B1 (pt) | 2022-07-05 |
| CN104244976B (zh) | 2017-05-31 |
| EP2763697B1 (en) | 2023-06-07 |
| US9770506B2 (en) | 2017-09-26 |
| KR20140093673A (ko) | 2014-07-28 |
| AU2012319265A1 (en) | 2014-05-22 |
| EA201490709A1 (ru) | 2014-09-30 |
| CN104244976A (zh) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03325A (es) | ||
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| BR112012007411A2 (pt) | composto, processo para sua preparação e composição farmacêutica contendo o mesmo | |
| MX2010007587A (es) | Compuestos que comprenden un grupo ciclobutoxi. | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| MY159252A (en) | Process for the preparation of dopo-derived compounds and compositions thereof | |
| BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| MY150596A (en) | Hsp90 inhibitors | |
| JO2910B1 (en) | Organic compounds | |
| MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| MX2011007952A (es) | Tricianoboratos novedosos. | |
| MX352607B (es) | Proceso para la preparacion de benzoxaboroles. | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| MY167638A (en) | Treatment composition for textile goods | |
| WO2009137444A3 (en) | Cure accelerators for anaerobic curable compositions | |
| NZ704155A (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
| BR112012009311A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BR112012009861A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| UY32975A (es) | Derivados de aminopiridina | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl | |
| MX2013003387A (es) | Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional. | |
| EA201390170A1 (ru) | Составы |